Immunosuppressant compound
AssigneeMerck & Co., Inc.
InventorsEdward S. Inamine, Byron H. Arison, Shieh-Shung T. Chen, Linda S. Wicker
Life of this patent
Estimating the term…
Abstract
Described is a process for producing a new immunosuppressant, "demethomycin" (L-682,993) a C-31 demethylated analog of L-679,934 under novel fermentation conditions utilizing the microorganism, Actinoplanacete sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in prevent human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
Claims10
A process for producing an immunosuppressant, identified as "demethomycin", comprising the step of culturing a strain of Actinoplanacete sp., together with L-679,934 under submerged aerobic fermentation conditions in an aqueous carbohydrate medium containing a nitrogen nutrient for a sufficient time to produce "demethomycin".
An immunosuppressant, "demethomycin", which exhibits positive inhibition IC.sub.50 of about 0.6 to 1.2.times.10.sup.-9 molar) of T-cell activation by the T-cell proliferation assay and a proton nuclear magnetic spectrogram as depicted in FIG. 1.
An immunosuppressant, "demethomycin", having a molecular structure as depicted in FIG. 3.
A pharmaceutical composition containing a therapeutically effective amount of "demethomycin" in combination with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
A method of use for treating a human host to prevent transplantation rejection, or for treating autoimmune disease or infectious disease comprising administering to said host a therapeutically effective amount of "demethomycin".
Dependencies are inferred from the claim text.